SNMMI 2017 in Denver: Booth 623

Siemens Healthineers Debuts Symbia Intevo Bold SPECT/CT

- New system allows customers to expand dual-use capabilities in CT
- New CT options enable lower patient dose, reduced metal artifacts for enhanced detail, and improved image quality via dual-energy scanning

At the 2017 annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI), June 10-14 at Denver’s Colorado Convention Center, Siemens Healthineers debuts Symbia Intevo Bold¹, a system that combines the company’s proven single-photon emission computed tomography (SPECT) technologies with new, high-performance CT capabilities to enable a wide range of clinical applications. These new CT options help make even challenging exams a matter of clinical routine. With products such as Symbia Intevo Bold, as well as a new name that underlines the company’s pioneering spirit and engineering expertise, Siemens Healthineers – the separately managed healthcare business of Siemens AG – helps healthcare providers worldwide meet current challenges and excel in their respective environments.

Symbia Intevo Bold addresses the growing trend of health care facilities using SPECT/CT systems in a dual-use setting, mirroring the rise of dual-use positron emission tomography (PET)/CT. More facilities are utilizing SPECT/CT systems as standalone or backup diagnostic CT systems. Additionally, institutions are looking to maximize efficiency for SPECT patients who also require a diagnostic CT scan by acquiring both sets of images on the same system. For these reasons, demand is increasing for SPECT/CT systems with optimal CT capabilities. Addressing that demand, the new Symbia Intevo Bold offers a host of optional applications that bolster the CT imaging capabilities of SPECT/CT.

“Symbia Intevo Bold advances the dual-use capabilities of SPECT/CT, enabling exceptional image quality in both forms of imaging at the lowest possible patient dose,” said Jim
Williams, head of Siemens Healthineers Molecular Imaging.

Available on a Siemens Healthineers SPECT/CT system for the first time, the SAFIRE² (Sinogram Affirmed Iterative Reconstruction) algorithm delivers excellent CT image quality while reducing patient radiation dose by as much as 60 percent. SAFIRE enables fast image reconstruction for easy implementation into a facility’s clinical routine. Additionally, SAFIRE reduces noise while maintaining detail visualization.

Also available for the first time on any of the company’s SPECT/CT systems, the iMAR³ (Iterative Metal Artifact Reduction) algorithm reduces metal-related artifacts caused by metallic materials, such as orthopedic and dental implants. With this capability, customers can not only curb or eliminate artifact-induced distortion in CT images but also apply the CT images for attenuation correction to provide a more enhanced, accurate SPECT image.

The optional IVR (interleaved volume reconstruction) feature of Symbia Intevo Bold reconstructs overlapping CT images up to 32 slices to extract the maximum amount of diagnostic information from measured data, enabling evaluation of small structures such as lesions or fractures. IVR improves spatial resolution in the z-direction of all CT scans, regardless of pitch.

Finally, the single-source dual energy capability of Symbia Intevo Bold employs two sequential spiral CT scans operating at different kV levels to combine tissue information with disease morphology, improving image quality. Post-processing applications with the company’s syngo Dual Energy software include monoenergetic, Calculi Characterization, and gout.

In addition to these CT-optimizing features, the Symbia Intevo Bold SPECT/CT system offers established cutting-edge capabilities in SPECT imaging. For example, xSPECT Quant⁴ quantification technology enables automated, accurate, and reproducible quantification of not only Technetium-99m – the most common isotope in SPECT imaging – but also Iodine-123, Lutetium-177⁵, and Indium-111. This capability extends the use of advanced SPECT quantification from general nuclear medicine and bone studies to indications including neurological disorders, neuroendocrine tumors, and prostate cancer.
¹ Symbia Intevo Bold is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

² SAFIRE is optional on Symbia Intevo Bold. In clinical practice, the use of SAFIRE may reduce CT patient dose depending on the clinical task, patient size, anatomical location, and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task. Data on file.

³ iMAR is optional on Symbia Intevo Bold. The amount of metal artifact reduction and corresponding improvement in image quality depends on a number of factors including: composition and size of the metal object, patient size, anatomical location and clinical practice. It is recommended to perform reconstructions with iMAR enabled in addition to conventional reconstruction without iMAR.

⁴ xSPECT Quant is not commercially available in all countries. Due to regulatory concerns, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

⁵ ¹⁷⁷Lu is not commercially available in some countries, including the U.S. ¹⁷⁷Lu is not currently recognized by the U.S. FDA as being safe and effective, and Siemens does not make any claims regarding its use. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Contact for journalists

Jeff Bell
Phone: (484) 868-8346; E-mail: jeffrey.t.bell@siemens-healthineers.com

This press release and a press picture is available at
www.siemens.com/press/PR2017060310HCEN

Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today’s dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide. Further information is available at www.siemens.com/healthineers.